肺癌组织中癌基因ras和c-myc蛋白产物的免疫组织化学研究  

Immunohistochemical study on the ras and c myc oncogene protein products in lung cancer

作　　者：李允模[1] 尹香花[1] 安昌善[1] 吴今子[1] 金河凤[1] 

机构地区：[1]延边大学医学院附属医院

出　　处：《延边大学医学学报》1999年第1期42-45,共4页Journal of Medical Science Yanbian University

摘　　要：目的］探讨肺癌组织中癌基因ｒａｓ和ｃｍｙｃ蛋白产物Ｐ２１，Ｐ６２表达特征以及临床病理意义．［方法］应用免疫组织化学方法（ＳＰ法）检测６９例肺癌组织标本中Ｐ２１和Ｐ６２蛋白表达．［结果］Ｐ２１和Ｐ６２在肺癌中的阳性表达率分别为６８％，７１％；在肺癌癌旁支气管粘膜和腺体中的阳性表达率分别为１８％和２９％，与肿瘤区相比较差异非常显著．Ｐ２１和Ｐ６２蛋白之间的阳性率无统计学差异．６９例肺癌中２１例（３０％）同时有Ｐ２１和Ｐ６２共同表达．肺腺癌Ｐ２１蛋白表达高于肺鳞癌．Ｐ２１和Ｐ６２蛋白表达与肺癌病人性别、年龄、肿瘤分期及肺癌分化程度无关．［结论］ｒａｓ和ｃｍｙｃ癌基因突变是肺癌的早期事件。Objective To find the expression feature and clinicopathological significance of the ras and c myc oncogene protein products in lung cancer.Method Immunohistochemical methods(S P method) were used to study the expression of P 21 and P 62 in 69 cases of lung cancer.Result The postive rate of P 21 and P 62 oncoproteins in lung cancer is 68% and 71% respectively; whereas that in tissues surrounding the cancer is 18% and 29% respectively. No Signficant difference is found between P 21 and P 62 oncoproteins expression in lung cancer.Co expression of the P 21 and P 62 oncoproteins are seen in 21 cases of lung cancer. No correlation are found between expression of P 21 ,P 62 and sex, age,differentiated or clinical tumor stage.Conclusion Mutations of the ras and c myc oncogenes are an early event in lung cancer.Both the ras and c myc oncogene have the same importance in the carcinogenesis and progression of lung cancer.

关 键 词：肺癌组织 癌基因蛋白P21 RAS C-MYC 免疫组化 

分 类 号：R734.203[医药卫生—肿瘤]